Results 11 to 20 of about 74,485 (196)

Nerve growth factor and Tropomyosin receptor kinase A are increased in the gastric mucosa of patients with functional dyspepsia

BMC Gastroenterology, 2019
Background Nerve growth factor (NGF) and enteric glial cells (EGCs) are associated with visceral hypersensitivity and gastrointestinal motility disorder, which may represent the pathogenesis of functional dyspepsia (FD).
Haitao Shi, Shanshan Zhu, Bin Qin, Lianli Wang, Juan Yang, Guolong Lu, Fei Dai   +6 more
doaj   +2 more sources

Larotrectinib Compared With Real-World Non-Tropomyosin Receptor Kinase Inhibitor Therapies in Patients With Tropomyosin Receptor Kinase Fusion Cancer. [PDF]

JCO Precis Oncol
PURPOSE Neurotrophic tyrosine receptor kinase gene fusions are oncogenic drivers of various solid tumors. Larotrectinib is a highly selective tropomyosin receptor kinase (TRK) inhibitor approved for patients with TRK fusion cancer on the basis of single ...
Brose MS, Westphalen CB, Pan X, Bernard-Gauthier V, Kurtinecz M, Guo H, Aris V, Brett NR, Majdi A, Subbiah V, Pennell NA, Kehl KL, Drilon A.   +12 more
europepmc   +2 more sources

Prevalence of neurotrophic tropomyosin receptor kinase (NTRK) fusion gene positivity in patients with solid tumors in Japan. [PDF]

Cancer Med
Members of the neurotrophic tropomyosin receptor kinase (NTRK) gene family, NTRK1, NTRK2, and NTRK3 encode TRK receptor tyrosine kinases. Intra‐ or inter‐chromosomal gene rearrangements produce NTRK gene fusions encoding fusion proteins which are ...
Nakata E, Osone T, Ogawa T, Taguchi T, Hattori K, Kohsaka S.   +5 more
europepmc   +2 more sources

Induction of resistance to neurotrophic tropomyosin‐receptor kinase inhibitors by HMGCS2 via a mevalonate pathway [PDF]

Cancer Medicine
Introduction A neurotrophic tropomyosin receptor kinase (NTRK)‐tyrosine kinase inhibitor (TKI) has shown dramatic efficacy against malignant tumors harboring an NTRK fusion gene.
Yasuhiro Kato, Masaru Matsumoto, Natsuki Takano, Mariko Hirao, Kuniko Matsuda, Takehiro Tozuka, Naomi Onda, Shinji Nakamichi, Susumu Takeuchi, Akihiko Miyanaga, Rintaro Noro, Akihiko Gemma, Masahiro Seike   +12 more
doaj   +2 more sources

Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer. [PDF]

Ann Oncol, 2019
The tropomyosin receptor kinase (TRK) family of receptor tyrosine kinases are encoded by NTRK genes and have a role in the development and normal functioning of the nervous system. Since the discovery of an oncogenic NTRK gene fusion in colorectal cancer
Amatu A, Sartore-Bianchi A, Bencardino K, Pizzutilo EG, Tosi F, Siena S.   +5 more
europepmc   +2 more sources

Identification and characterization of the Cucurbitacins, a novel class of small-molecule inhibitors of Tropomyosin receptor kinase a [PDF]

BMC Complementary and Alternative Medicine, 2019
Background NGF-TrkA is well known to play a key role in propagating and sustaining pruritogenic signals, which form the pathology of chronic pruritus. Inhibition of NGF-TrkA is a known strategy for the treatment of pruritus.
Yueling Zhong, Hong Xu, Yi Zhong, Xuemiao Zhang, Ting Zeng, Limei Li, Gaojie Xu, Minhui Li, Jin Liu, Tai Yang   +9 more
doaj   +2 more sources

Targeting the Nerve Growth Factor Signaling Impairs the Proliferative and Migratory Phenotype of Triple-Negative Breast Cancer Cells

Frontiers in Cell and Developmental Biology, 2021
Triple-negative breast cancer is a heterogeneous disease that still lacks specific therapeutic approaches. The identification of new biomarkers, predictive of the disease’s aggressiveness and pharmacological response, is a challenge for a more tailored ...
Marzia Di Donato, Giovanni Galasso, Pia Giovannelli, Antonio A. Sinisi, Antimo Migliaccio, Gabriella Castoria   +5 more
doaj   +1 more source

Brazilian Expert Consensus for NTRK Gene Fusion Testing in Solid Tumors

Clinical Pathology, 2023
Oncogenic neurotrophic tropomyosin receptor kinase gene fusions occur in less than 1% of common cancers. These mutations have emerged as new biomarkers in cancer genomic profiling with the approval of selective drugs against tropomyosin receptor kinase ...
Mariana Petaccia de Macedo, Ellen Caroline Toledo Nascimento, Fernando Augusto Soares, Fernando Costa Santini, Felipe D’Almeida Costa, Isabela Werneck da Cunha, Rodrigo Ramella Munhoz, Pedro De Marchi, Thiago William Carnier Jorge, Kátia Ramos Moreira Leite   +9 more
doaj   +1 more source

NTRK Fusion in Non-Small Cell Lung Cancer: Diagnosis, Therapy, and TRK Inhibitor Resistance

Frontiers in Oncology, 2022
Neurotrophic tropomyosin receptor kinase (NTRK) gene fusion has been identified as an oncogenic driver of various solid tumors, and it is rare in non-smalll cell lung cancer (NSCLC) with a frequency of approximately less than 1%.
Fangfang Liu, Yuxuan Wei, Huan Zhang, Jizong Jiang, Peng Zhang, Qian Chu   +5 more
doaj   +1 more source

gene amplification in patients with metastatic cancer [PDF]

Precision and Future Medicine, 2017
Purpose Neurotropic tropomyosin receptor kinase (NTRK) fusions have been identified in a variety of cancers, and tyrosine kinase inhibitors targeting the tropomyosin receptor kinase (TRK) receptor are currently in clinical trials. However, no reports are
Su Jin Lee, Nayoung K. D. Kim, Se-Hoon Lee, Seung Tae Kim, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Woong Yang Park, Hee Jin Bang, Kyoung-Mee Kim, Keunchil Park, Jeeyun Lee   +13 more
doaj   +1 more source